MX2020008326A - Formas de co-cristales de un analogo de novobiocina y prolina. - Google Patents

Formas de co-cristales de un analogo de novobiocina y prolina.

Info

Publication number
MX2020008326A
MX2020008326A MX2020008326A MX2020008326A MX2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A
Authority
MX
Mexico
Prior art keywords
proline
crystal forms
novobiocin
analog
dimethyltetra
Prior art date
Application number
MX2020008326A
Other languages
English (en)
Spanish (es)
Inventor
Xin Jiang
John Allen Walling
Melanie J Bevill
Christopher S Seadeek
Jared P Smit
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2020008326A publication Critical patent/MX2020008326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
MX2020008326A 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina. MX2020008326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
MX2020008326A true MX2020008326A (es) 2020-09-28

Family

ID=65444361

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008326A MX2020008326A (es) 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina.
MX2022012856A MX2022012856A (es) 2018-02-07 2020-08-06 Formas de co-cristales de un analogo de novobiocina y prolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012856A MX2022012856A (es) 2018-02-07 2020-08-06 Formas de co-cristales de un analogo de novobiocina y prolina.

Country Status (19)

Country Link
US (3) US10717755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749675B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021512910A (cg-RX-API-DMAC7.html)
KR (2) KR102718111B1 (cg-RX-API-DMAC7.html)
CN (2) CN112020506B (cg-RX-API-DMAC7.html)
AR (1) AR114245A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019217821B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016205A2 (cg-RX-API-DMAC7.html)
CA (2) CA3090646C (cg-RX-API-DMAC7.html)
CL (2) CL2020002051A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009761A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091885A1 (cg-RX-API-DMAC7.html)
IL (2) IL315865A (cg-RX-API-DMAC7.html)
MX (2) MX2020008326A (cg-RX-API-DMAC7.html)
MY (1) MY209803A (cg-RX-API-DMAC7.html)
PE (1) PE20211446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007530XA (cg-RX-API-DMAC7.html)
TW (3) TWI868593B (cg-RX-API-DMAC7.html)
WO (1) WO2019156907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
BR112014019704B1 (pt) * 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CA3289739A1 (en) 2014-06-24 2025-11-29 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
KR20240155354A (ko) 2024-10-28
AU2019217821B2 (en) 2022-09-08
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
US11401294B2 (en) 2022-08-02
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
WO2019156907A1 (en) 2019-08-15
AU2019217821A1 (en) 2020-09-24
US20190241599A1 (en) 2019-08-08
EA202091885A1 (ru) 2021-01-15
IL276583A (en) 2020-09-30
CL2020002051A1 (es) 2021-02-19
AR114245A1 (es) 2020-08-12
TW202510893A (zh) 2025-03-16
CN112020506B (zh) 2024-10-11
CN118894894A (zh) 2024-11-05
JP2021512910A (ja) 2021-05-20
US10717755B2 (en) 2020-07-21
KR102718111B1 (ko) 2024-10-17
CO2020009761A2 (es) 2020-10-30
TW201945381A (zh) 2019-12-01
EP3749675A1 (en) 2020-12-16
MY209803A (en) 2025-08-05
IL276583B2 (en) 2025-03-01
NZ767558A (en) 2024-11-29
BR112020016205A2 (pt) 2020-12-15
AU2022283638A1 (en) 2023-02-02
US20240043465A1 (en) 2024-02-08
CA3090646C (en) 2024-02-27
PE20211446A1 (es) 2021-08-05
TWI797249B (zh) 2023-04-01
TWI868593B (zh) 2025-01-01
US20200347088A1 (en) 2020-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
AU2024227646A1 (en) 2024-11-14
CL2022003784A1 (es) 2023-06-09
JP2026012851A (ja) 2026-01-27
CA3090646A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
TWI915111B (zh) 2026-02-11
EP3749675B1 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
NZ629778A (en) C-terminal hsp90 inhibitors
CL2022003784A1 (es) Formas co-cristalinas de un análogo de novobiocina y prolina
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CR20210381A (es) MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158)
JOP20210154B1 (ar) مثبطات kif18a
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
EA202092086A1 (ru) Ингибиторы аргиназы
MX2022005256A (es) Inhibidores de cd73.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
CR20210442A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214)
EA201990949A1 (ru) Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EP3986873C0 (en) 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
EP3903806A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY TRPV1 ACTIVITY
FR3075012B1 (fr) Procede de traitement cosmetique par plasma froid
EP3991727A4 (en) Composition for treating degenerative brain diseases, containing 2-pentylfuran as active ingredient
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA201692185A1 (ru) Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
BR112017015474A2 (pt) inibidores de bace1
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
CL2011003165A1 (es) Compuestos derivados de 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; composicion farmaceutica; y su uso para el tratamiento o la prevencion de trastornos melatoninergicos tales como depresion, estres, trastornos del sueño, insomnio, diabetes, enfermedad de parkinson, enfermedad de alzheimer entre otros.
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение